Pfizer (NY:PFE)

28.46 -0.06 (-0.20%)

Delayed Quote Updated: 11:11 AM EDT, Oct 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

99 100 Next >

Curious about the most active stocks on Tuesday? ↗

December 16, 2025

Discover the most active stocks in Tuesday's session. Stay informed about the stocks that are generating the most trading volume!

Via Chartmill

1 Bold Prediction for Viking Therapeutics in 2026 ↗

December 16, 2025

Viking's pipeline may release its value next year, and larger companies are likely to consider acquiring it.

Via The Motley Fool

Pfizer Stock On-Track For Worst Day In Over 8 Months As BofA Flags Faster Covid-19 Product Erosion ↗

December 16, 2025

The company now expects full year 2025 guidance of about $62 billion, to the lower end of its previous guidance of $61 to $64 billion and below an analyst estimate of $62.52 billion.

Via Stocktwits

These S&P500 stocks are moving in today's session ↗

December 16, 2025

Stay informed about the performance of the S&P500 index in the middle of the day on Tuesday. Uncover the top gainers and losers in today's session for valuable insights.

Via Chartmill

Deep Dive: Windlas Biotech Limited – A Pharmaceutical Growth Story

December 16, 2025

As of December 16, 2025, Windlas Biotech Limited (NSE: WINDLAS, BSE: 543403) stands as a significant player in India's burgeoning pharmaceutical sector, primarily recognized for its robust contract...

Via PredictStreet

Topics Initial Public Offering

Pfizer Shares Fall As 2026 Outlook Reflects Weaker COVID-19 Drug Demand ↗

December 16, 2025

Pfizer shares fell after the company issued weaker-than-expected 2026 guidance, citing lower demand for COVID-19 products and upcoming patent expirations.

Via Talk Markets

Topics Intellectual Property

These S&P500 stocks are gapping in today's session ↗

December 16, 2025

Let's have a look at what is happening on the US markets on Tuesday. Below you can find the S&P500 gap up and gap down stocks in today's session.

Via Chartmill

Why Pfizer's 2026 Guidance Miss Is 'Not A Major Surprise' ↗

December 16, 2025

Pfizer issued a light outlook for 2026 on Tuesday, missing Wall Street's earnings forecast following a suite of acquisitions.

Via Investor's Business Daily

Pfizer Sees Slower 2026 Growth Despite Pipeline Push, Cost Cuts ↗

December 16, 2025

Pfizer previews 2026 guidance with earnings below consensus, softer sales outlook, COVID decline and LOE headwinds offset by pipeline growth.

Via Benzinga

Pfizer Adds to Its Big Bet on Weight Loss Drugs ↗

December 16, 2025

Via MarketBeat

Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance

December 16, 2025

From Pfizer Inc.

Via Business Wire

Where Will Eli Lilly Be in 10 Years? ↗

December 16, 2025

In a decade, Eli Lilly could be in the same place that Pfizer finds itself in today.

Via The Motley Fool

Topics Intellectual Property

These S&P500 stocks are the most active in today's session ↗

December 15, 2025

Explore the S&P500 index on Monday and find out which stocks are the most active in today's session. Stay updated with the stocks that are capturing market interest.

Via Chartmill

Pfizer Faces Another Quiet Year As Patent Losses Cloud 2026 Outlook: Analyst ↗

December 15, 2025

Pfizer to provide full-year 2026 financial guidance on Tuesday. BofA analyst expects flat growth, reiterates Neutral rating.

Via Benzinga

Topics Intellectual Property

Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer

December 15, 2025

From Adaptive Biotechnologies

Via GlobeNewswire

Will Dogecoin Reach $1 By the End of the Year? ↗

December 15, 2025

Dogecoin's price would need to rise more than seven-fold before the calendar turns to 2026.

Via The Motley Fool

Topics Artificial Intelligence

Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead? ↗

December 14, 2025

Teva Pharmaceutical is a leader in generic drugs, but these struggling makers of branded drugs may be a better choice.

Via The Motley Fool

Topics Intellectual Property

Forget Teladoc and Buy This Healthcare Stock Instead ↗

December 13, 2025

It's time for investors to give up on the telemedicine leader.

Via The Motley Fool

Rigani Press Announces Barnes & Noble Book Signing for Dr. S. Yin Ho's Groundbreaking Book

December 12, 2025

Via PRLog

Topics Artificial Intelligence

Pfizer Declares First-Quarter 2026 Dividend

December 12, 2025

From Pfizer Inc.

Via Business Wire

Pfizer Is Still Struggling to Replace Its COVID Revenue. Here's What We Could See From the Pharmaceutical Giant in 2026. ↗

December 12, 2025

Keep your expectations in check.

Via The Motley Fool

The Best Turnaround Stock to Invest $1,000 in Right Now ↗

December 12, 2025

Pfizer and Bristol Myers Squibb are deeply out-of-favor drugmakers, but one could be the better turnaround candidate if you think long term.

Via The Motley Fool

The Great Divergence: Investors Retreat from High-Flying Tech as Market Seeks New Equilibrium

December 11, 2025

The financial markets are witnessing a significant "Great Divergence" as investor sentiment pivots sharply away from the high-flying technology stocks that have dominated portfolios for years. As of...

Via MarketMinute

Topics Artificial Intelligence Economy Law Enforcement

Great Rotation: Tech Exodus Fuels Dow's Record Run While Nasdaq Struggles

December 12, 2025

As of December 12, 2025, the financial markets are witnessing a significant "Great Rotation," a pronounced shift of capital from high-growth technology and Artificial Intelligence (AI) stocks to more...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

Value Stocks Stage a Comeback Bid Amidst Persistent Growth Dominance

December 11, 2025

The financial markets in late 2025 present a complex narrative, a tug-of-war between the long-reigning titans of growth and a resurgent, yet often overshadowed, cohort of value stocks. While the...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Moderna And Super Micro Top S&P 500 Short Interest List — Are They Ripe For A Squeeze? ↗

December 11, 2025

Investors remain divided on Moderna and Super Micro as heavy short interest reflects skepticism, yet recent catalysts suggest both names could still deliver unpredictable, sentiment-driven swings.

Via Stocktwits

Topics Artificial Intelligence Stocks

Warning: This Skyrocketing Stock Has a Hidden Risk ↗

December 10, 2025

Following a significant price increase due to the company's industry-leading weight loss drugs, investors must now consider what comes next.

Via The Motley Fool

Topics Intellectual Property

Pfizer's Tukysa Combo Shows Strong PFS Benefit In Metastatic Breast Cancer ↗

December 10, 2025

Pfizer reports Phase 3 results showing Tukysa with trastuzumab and pertuzumab prolonged progression-free survival by 8.6 months in HER2+ metastatic breast cancer.

Via Benzinga

Markets Brace for Anticipated Fed Rate Cut Amidst Shifting Economic Landscape

December 10, 2025

As December 2025 draws to a close, financial markets are holding their breath in anticipation of a pivotal Federal Reserve interest rate decision. Investopedia's analysis reveals a pervasive market...

Via MarketMinute

Topics Artificial Intelligence Bonds Credit Cards

TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer

December 10, 2025

From Pfizer Inc.

Via Business Wire

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.